| |
More than 50% of all infants, both pre-term and full-term, are at risk of hyperbilirubinemia, a condition caused when there is too much bilirubin in the blood. To address this condition, GE Healthcare, a unit of General Electric Company (NYSE:GE), has introduced a LED phototherapy product to their Lullaby portfolio, further addressing the needs of infants around the world.
Recently receiving CE Marking, the Lullaby LED phototherapy system equips clinicians with a tool to deliver high intensity phototherapy to treat infants with hyperbilirubinemia. By utilizing LED technology, power consumption and the overall replacement costs are significantly reduced, resulting in up to 80% energy savings and a 50x extended bulb life, making Lullaby1 LED phototherapy an investment for today and tomorrow.
“Providing clinicians with the right tools to address infants’ healthcare needs, like hyperbilirubinemia is the foundation of our business,” stated Carrie Eglinton Manner, General Manager of GE Healthcare’s Material Infant Care business. “The Lullaby LED phototherapy system is a great addition to our Lullaby performance product portfolio and offers a safe, efficient and cost effective solution to address one of the most common ailments in newborns.”
In addition to the overall savings, Lullaby LED phototherapy:
• Is quiet; designed without a fan and operating over 50% quieter than IEC guidelines;
• Provides a tightly focused wavelength for maximizing bilirubin metabolism;
• Has a high irradiance level allowing for tailored treatment for each infants’ needs;
• Delivers uniform light distribution over the total surface area of the body, maximizing bilirubin breakdown.
Through the combination of optimal wavelength, high intensity and uniform light distribution yields a 28% faster total serum bilirubin breakdown2.
About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.
For our latest news, please visit newsroom.gehealthcare.com/.
* GE, GE Monogram and Lullaby are trademarks of General Electric Company
1 Not commercially available in all markets; not cleared or approved by the U.S. FDA.
2 Based on calculations from Osaku NO, Lopes HS. A dose response model for the conventional phototherapy of the newborn. Journal of Clinical Monitoring and Computing. 2006, 20(3): 159-164
|
Annette.Busateri[.]ge.com 
